Histopatologia Del Aborto Espontaneo Entre 12 Y 22 Semanas

S, Alfredo Ovalle; W, Elena Kakarieka; P, María Teresa Vial; R, Reinaldo González; P, Angel Correa; G, Mohamed Sukni; P, Jorge Figueroa

doi:10.4067/s0717-75262003000500002

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To conserve the activity of the targeting ligand and the payload efficacy, the linker should also be meticulously modified to optimize drug release, pharmacokinetic and pharmacodynamic properties, and the function of the targeting ligand or payload. 11,12 The principle of this conjugation technique is to use targeting ligands to partially specifically target receptors on the surface of tumor cells, thereby increasing the local concentration of the drug at the lesion site and reducing the toxic effects on normal tissues. When these conjugates are recognized by intracellular integrin receptors and ingested into cells through endocytosis, under certain biological conditions (e.g., different pH values), the chemical bond between the linked drug and the targeting ligand can be degraded, leading to the selective release of the drug into the nucleus and its antitumor effect.…”

Section: Introductionmentioning

confidence: 99%

Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment

Wang,

Li,

Wei

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Antibody drug conjugates (ADCs) have emerged as a new promising class of anti-cancer agents. However, limitations such as higher costs and unavoidable immunogenicity due to their relatively large structures cannot be ignored. Therefore, the development of lightweight drugs such as small molecule−drug conjugates (SMDCs) based on the ADC design idea has become a new option for targeted therapy. SMDCs are derived from the coupling of small-molecule targeting ligands with cytotoxic drugs. They are composed of three parts: small-molecule targeting ligands, cytotoxic molecules, and linkers. Compared with ADCs, SMDCs can be more rapidly and evenly dispersed into tumor tissues, with low cost and no immunogenicity. In this article, we will give a comprehensive review of different types of SMDCs currently under clinical trials to provide ideas and inspirations for the development of clinically applicable SMDCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment

Wang,

Li,

Wei

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Rev Peru Investig Matern Perinat 2020;9(4):43-48 Remy Paredes N. et al El tumor trofoblástico del lecho placentario está constituido por trofoblasto mononuclear intermedio no conteniendo vellosidades coriónicas e Inmunohistoquimicamente caracterizado por expresar muchas de sus células HPL y unas pocas HCG [1][2][3][4] .…”

unclassified

Aborto retenido con degeneración vesicular

Paredes¹,

Limas²,

Arango-Ochante³

2021

Investigación Materno Perinatal

View full text Add to dashboard Cite

Paciente mujer de 36 años de edad con amenorrea de 6 semanas, ingresa al servicio de emergencia de ginecología y obstetricia por dolor pélvico asociado a sangrado vaginal escaso y aumento de tamaño del útero para la edad gestacional, con niveles de b-hcg elevados, sospechando un embarazo molar. Se realiza un ameu evidenciandose restos ovulares y vesiculas perladas caracteristicas de la patologia en mencion, sin embargo, los resultados de anatomia patologica informan muerte fetal a decartar mala perfusion materna fetal. De este caso se rescata las diferentes formas de presentación que puede presentar un aborto

show abstract

Histopatologia Del Aborto Espontaneo Entre 12 Y 22 Semanas

Cited by 2 publications

References 0 publications

Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment

Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment

Aborto retenido con degeneración vesicular

Contact Info

Product

Resources

About